ICON6 is a randomised three-arm, three stage, double-blind, placebo-controlled multicentre Gynaecologic Cancer InterGroup (GCIG) phase III trial, designed to evaluate the safety and efficacy of platinum-based chemotherapy incombination with cediranib in women with platinum-sensitive relapsed ovarian cancer. Cediranib (AZD2171) will be administeredduring platinum-based chemotherapy only (concurrent cediranib), or given duringchemotherapy and continued as single agent (maintenance therapy) for up to 18 months(concurrent and maintenance cediranib).
Acutely Manic Patients Insufficiently Responding After 2 Weeks Continued Quetiapine Monotherapy: Continued Quetiapine Versus Sodium Valproate Add-on.
Development of an algorithm for identification of responders to short term treatment with esomeprazol (Nexium) in primary care. - PPI Response Trial
100 Clinical Results associated with Astrazenica Continent BV
0 Patents (Medical) associated with Astrazenica Continent BV
100 Deals associated with Astrazenica Continent BV
100 Translational Medicine associated with Astrazenica Continent BV